Abstract IgA nephropathy is the world's most common primary glomerulonephropathy. Recent evidence in a rat model implicated excessive production of oxygen-free radicals in the pathogenesis and suggested that vitamin E-treatment ameliorated progression. We studied this antioxidant therapy on the glomerular filtration rate (GFR), proteinuria and hematuria in biopsy-proven IgA nephropathy in children. The duration of treatment or placebo was 2 years, with vitamin E treatment consisting of 400 IU/day in children weighing <30 kg, and twice that dose for those >30 kg. We measured GFR at entry, midpoint and exit. At baseline and at 4-month intervals after randomization, urinary protein/creatinine ratios and urinalysis were examined. The mixed model procedure with log transformation was used in data analysis to test treatment difference as well as the potential time effect. Fifty-five patients were randomized and 38 completed at least 1 year of follow-up. At entry, the clinical characteristics were not different between the treatment and placebo groups. There was a trend toward better preservation of GFR in vitamin E-treated versus placebo patients, 127±50 vs. 112±31 ml/min/1.73 m 2 , respectively (P=0.09). The urinary protein/creatinine ratio was significantly lower in the vitamin E-treated group vs. placebo; 0.24±0.38 vs. 0.61±1.37 (P<0.013). However, there was no difference in the prevalence of hematuria between the groups. Vitamin E treatment in our study patients was associated with significantly lower proteinuria, but no effect on hematuria. While there was a trend toward stabilization of GFR in the vitamin E-treated patients, longterm treatment and follow-up are needed to determine whether antioxidant therapy is associated with preservation of renal function in IgA nephropathy.
Introduction
The end-stage renal disease program of chronic dialysis/kidney transplantation costs the nation $15.64 billion/year [1] . IgA nephropathy accounts for 10-30% of patients in end-stage renal failure [2, 3, 4, 5, 6] . The long-term prognosis in children, previously presumed to be less serious than in adults with this condition, has recently been shown to be no different, with 25% of children with biopsy-proven IgA nephropathy progressing to end-stage renal disease in 20 years [7, 8] .
The pathogenesis of IgA nephropathy is unclear [9, 10] and there are no proven therapies that reverse the progressive glomerulosclerosis which leads to end-stage kidney disease [11] . Recently, we documented increased oxygen-free radical release in an experimental rat model of IgA nephropathy [12] . Administration of a diet that was modestly enriched in vitamin E ameliorated renal functional deterioration and prevented glomerular damage. This protective effect was associated with a decrease in renal cortical malondialdehyde content [12] . This demonstration that oxygen-free radical injury contributes to the pathogenesis of IgA nephropathy and that antioxidant therapy can decrease glomerular injury [12] is in accordance with recent studies which indicate that peripheral polymorphonuclear leukocytes isolated from patients with IgA nephropathy generate increased amounts of superoxide radicals [13, 14] and IgA-containing immune-complexes stimulate production of oxygen-free radicals by mesangial cells in situ [15] . In parallel with enhanced superoxide production, aggregated IgA induced Fcα receptor expression in leukocytes [13, 14] . These findings were correlated with the severity of proteinuria in patients with IgA nephropathy [13, 14, 16] .
We conducted a pilot study consisting of an interventional human trial using a randomized, placebo-controlled prospective design in biopsy-proven IgA nephropathy from a network of seven pediatric nephrology programs.
Materials and methods

Study subjects and procedures
This pilot study was prospective, double blinded and placebo controlled. Institutional Review Board approval was obtained for each of the seven participating pediatric nephrology programs. Patients were approached by the investigator to participate in the study. The purpose and procedures of the investigation were explained to the parents or the legal guardian and to the child. Written informed consent obtained from the parent or guardian, and where appropriate from the child, was sent to the centralized Data Coordinating Center (DCC). The DCC reviewed the signed consent form, clinical record, and renal biopsy for entry into the study. Randomization to placebo or treatment arms was generated by a computer to achieve a balance between the two groups, so that baseline characteristics of gender, ethnic group, height, weight, blood pressure and geographic distribution were accounted for.
Primary IgA nephropathy, confirmed by the index renal biopsy at the participating center with IgA deposition in the mesangium, qualified for entry. Entry criteria also included patients with documented hematuria (more than three erythrocytes per high-power field in spun urine sample) [17] on two occasions during the prerandomization period and a glomerular filtration rate between 20% and 100% of normal for age. The choice of a lower limit of glomerular filtration rate lessened the likelihood of a patient exiting to dialysis and/or transplantation during the period of the study. The age of entry was less than 21 years of age.
The exclusion criteria were as follows: (1) secondary IgA nephropathy associated with organ transplantation, HIV+, diabetes mellitus, lupus nephritis, Alport syndrome, anaphylactoid purpura nephropathy, chronic liver diseases (hepatitis, biliary tract obstruction), gastrointestinal diseases (celiac disease, Crohn disease, adenocarcinoma), respiratory diseases (chronic obstructive bronchiolitis, idiopathic interstitial pneumonia), dermatitis herpetiformis, mycosis fungoidis, leprosy, episcleritis, anterior uveitis, ankylosing spondylitis, relapsing polychondritis, schistosomiasis, Sjogren syndrome, monoclonal IgA gammapathy and pregnancy; (2) previous treatment with vitamin E, corticosteroid, cyclosporin, tacrolimus, warfarin, persantin, phenytoin, fish oil, omega 3-polyunsaturated fatty acid, danazol, dapsone, dipyridamole, urokinase, sodium cromoglycate, plasmaphoresis, angiotensin-converting enzyme inhibitor, tonsillectomy or Cordyceps sinensis (Chinese herbal medicine); (3) pregnancy; and (4) hypertension, as defined vide infra.
The exit criteria were: (1) dialysis/transplantation, as well as hypertension (vide infra); (2) medical non-compliance (after two consecutive warnings), documented by self-admission, medication package counts, and serum vitamin E concentration; and (3) failure to report for two consecutive follow-up visits. The reasons for exit were reported to the Data Coordinating Center and the Principal Investigator. Within reason, patients who exited the study continued to be followed.
The primary endpoints were changes in GFR and proteinuria as indices of progression and response to therapy. The prevalence of hematuria was a secondary endpoint.
Treatment
Patients received one or two placebos or vitamin E capsules, which were identical in appearance. Children less than 30 kg body weight received one capsule of 400 IU vitamin E/day; children of 30 kg body weight or above received two capsules of 400 IU/day. Hoffman-La Roche Inc. provided both placebo and the vitamin E capsules. These were enclosed in 30-day medication packages (Remind-A-Pac, Southfield, MI) [18] . A back-up 1-month package was always made available for each patient at the respective clinics.
Clinic visits and laboratory tests
At entry these parameters were obtained: height, weight, blood pressure, physical examination, urinalysis of fresh early morning specimen, and urine protein to creatinine ratio, 24-h creatinine clearance, fasting serum electrolytes, urea nitrogen, creatinine and vitamin E.
Hypertension was defined by diastolic blood pressure exceeding the 95th percentile above normal for age documented on three occasions in a quiet and relaxed setting. Hypertension or the use of an antihypertensive medication was cause for exclusion or exit. All exited patients continued as per this protocol, but their data were separately analyzed.
At follow-up every 4 months, these parameters were obtained: height, weight, blood pressure, physical examination, early morning urine protein/creatinine, urinalysis, serum electrolytes, urea nitrogen, creatinine and vitamin E. At annual intervals or study exit 24-h creatinine clearance was repeated.
Microscopic urinalysis
The early morning, "clean catch" or clean-void and mid-stream sample was the specimen of choice [17] . The analysis was done by the investigator at the participating center. After mixing the fresh specimen, 10-15 ml of urine was centrifuged at 2000 rpm for 5 min. The supernatant fluid was poured off and the resuspended sediment mixed. A drop of sediment on a clean slide was prepared for microscopic examination in subdued light [17] . The number of red cells per high-power field was counted and reported. Red cells, dysmorphic red cells, red cell casts and other elements [17] were recorded.
Routine chemistry methods for urinalysis, urine protein and creatinine clearances Routine laboratory procedures for dipstick urinalysis, protein and creatinine of an early morning voiding were performed at the participating centers. The standard 24-h creatinine clearances for glomerular filtration rate were determined [19, 20] .
Serum vitamin E concentration
Serum vitamin E concentration was determined as an index of compliance, using the high-pressure liquid chromatography (HPLC) method [21] . Specimens for vitamin E concentrations were obtained at the participating centers and sent to the DCC for analysis.
Statistical methods
The biostatistician was blinded to the treatment code, which was not broken until data analysis was completed. The urinary protein to creatinine ratio was analyzed by the mixed model procedure [22] . The analysis was based on the log transformation of the ratio [23] and both the treatment difference and the potential time effects were examined.
In analyzing the prevalence of hematuria, two approaches were used: (1) either heme positive or heme negative on a dipstick of a fresh urine sample or (2) positive or negative for three or more red blood cells per high-power field in a fresh urine sample. The chisquare test was used to test the differences between the placebo and treatment arms.
The creatinine clearances were analyzed by Student's t-test [23] based on the log transformed data.
Results
From 1 January 1997 to 1 August 2000, 62 patients with IgA nephropathy were evaluated and 55 who met the entry and exclusion criteria consented to enroll in the study. Twenty-eight were randomized to receive placebo and 27 received vitamin E.
Baseline characteristics
The clinical and laboratory characteristics of the two groups were similar at randomization (Table 1) in terms of gender, ethnic group, height, weight, blood pressure, prevalence of hematuria, degree of proteinuria and creatinine clearance.
Study outcome
The serum α-tocopherol concentration increased significantly (P<0.001) from 0.84±0.25 mg/dl (mean ± SD) in the placebo patients to 1.85±0.77 in the treated patients. The creatinine clearances at the end of the study showed values of 112±31 ml/min/1.73 m 2 in the placebo versus values of 127±50 ml/min/1.73 m 2 in the treated patients (P=0.09). None suffered a significant decline in GFR.
The data showed that there was no difference in the prevalence of hematuria, either tested by +heme reaction on dipstick or by red blood cells per high-power field. The urinary protein to creatinine ratio showed a significant drop (P=0.013) from the placebo group (0.61±1.37 mg/mg) to the values in the treated group (0.24±0.38 mg/mg).
No patients exited the study to end-stage kidney disease, dialysis or transplantation. Patients dropped out of the study due to self-administration of vitamin E and failure to keep two consecutive follow-up clinic appointments.
Safety
There were no complaints or untoward complications from either group of patients. 
Discussion
In this investigator-initiated and NIH-funded pilot study, vitamin E therapy was associated with a significant reduction in the proteinuria of children with biopsy-proven IgA nephropathy, but with no significant changes in the prevalence of hematuria. The results raise the possibility of a renoprotective effect of vitamin E in IgA nephropathy.
In a recent study, Chitalia et al. [24] showed that spot urine protein to creatinine ratio (between 0.26 and 3.20 mg/mg) agrees closely with 24-h urine protein along a wide range of renal function and glomerular diseases. Their study [24] strengthens the validity of our using early morning, spot urine protein to creatinine ratio. Our pilot data, therefore, support the promise of a fullscale trial to test the efficacy of antioxidants in long-term treatment of IgA nephropathy, including a focus on urinary microalbuminuria [25] and new molecular biomarkers, e.g., urinary nephrin genes [26] , as indices of renal injury or recovery.
The difficulty in using an antioxidant, e.g., vitamin E, in clinical trials lies in the fact that patients often want to self-administer this over the counter, inexpensive product, with no clinically relevant side effects. However, the significantly low serum α-tocopherol concentrations in the placebo patients compared to the higher values in the treated patients attest to patient compliance. It is a credit to the patients' families and the bond with the clinical investigators that medical compliance was excellent throughout the study.
In experimental IgA nephropathy, Trachtman et al. [12] demonstrated that vitamin E treatment was associated with a significant reduction of proteinuria, as we now confirm in this pilot study. In contrast to the unchanged prevalence of hematuria in our human study, the animal studies of Trachtman et al. [12] showed a significant reduction in the incidence of hematuria. Whether doubling or tripling of the current dose of vitamin E might have an effect on the prevalence of hematuria is conjectural. A dose response study, similar to that conducted in experimental IgA nephropathy [27] , is outside the purview of our study aim. A dose response study will require a larger consortium of centers to provide the requisite number of patients. Similar to our TGFβ1 data for our rat model of IgA nephropathy [12] , increased glomerular TGFβ1 mRNA in patients with IgA nephropathy has been demonstrated by Naka et al. [16] . The progression of IgA nephropathy may result from overexpression of TGFβ1 leading to mesangial matrix expansion, interstitial fibrosis, and glomerulosclerosis. We hypothesize that the interception of autocrine activation of TGFβ1 by the natural antioxidant, vitamin E, may check disease progression in IgA nephropathy [12] .
Finally, creatinine clearance remained well preserved in both placebo and treated groups. However, the estimate of GFR used in this study may not be sensitive enough to detect loss of renal function over the relatively short duration of observation of our trial [26] . For IgA nephropathy, a slowly progressive disease where 25-30% of patients continue over a quarter century to end-stage renal disease [2, 3, 4] , a full-scale, longer duration clinical trial with more accurate measurement of glomerular filtration rate [28] will be needed for valid generalization.
It should be noted that the disease in our patients was in the early and mild stages. There is a need to extend these findings to more severely affected patients with IgA nephropathy and to follow such patients for an extended period of time.
The data of the present pilot study were not designed to test this question but may lead to the use of vitamin E either alone or as an adjunct medication in early IgA nephropathy to slow the rate of progression of this common primary glomerular disease.
